Who
Erick Gamelin
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Acrivon Therapeutics.
In numbers
- Trades disclosed
- 23
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $1,608
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Nov 2022
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $804400 at $2.01 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $804400 at $2.01 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —38,584 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —38,584 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $776404 at $1.92 | filing |
| 14 May 2026filed 18 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $776404 at $1.92 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,946 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,946 at $0.00 | filing |
| 14 Feb 2026filed 18 Feb 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $768471 at $1.63 | filing |
| 14 Feb 2026filed 18 Feb 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $768471 at $1.63 | filing |
| 14 Nov 2025filed 18 Nov 2025 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $903403 at $2.24 | filing |
| 14 Aug 2025filed 18 Aug 2025 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $560403 at $1.39 | filing |
| 14 May 2025filed 16 May 2025 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $459403 at $1.14 | filing |
| 1 Mar 2025filed 4 Mar 2025 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,078 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,542469 at $5.42 | filing |
| 14 Nov 2024filed 18 Nov 2024 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $3,184402 at $7.92 | filing |
| 14 Aug 2024filed 16 Aug 2024 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,822402 at $7.02 | filing |
| 14 May 2024filed 16 May 2024 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $3,361402 at $8.36 | filing |
| 1 Mar 2024filed 27 Nov 2024 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,045 at $0.00 | filing |
| 14 Feb 2024filed 16 Feb 2024 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,591468 at $3.40 | filing |
News
No headline names them, or the companies they trade most, lately.